By Mill Chart
Last update: Mar 18, 2024
Take a closer look at NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO), a stock of interest to dividend investors uncovered by our stock screener. NYSE:NVO excels in fundamentals and provides a decent dividend, all while maintaining a reasonable valuation. Let's break it down further.
ChartMill assigns a Dividend Rating to every stock. This score ranges from 0 to 10 and evaluates the different dividend aspects, including the yield, the growth and sustainability. NYSE:NVO scores a 7 out of 10:
ChartMill employs its own Health Rating for stock assessment. This rating, ranging from 0 to 10, is calculated by examining various liquidity and solvency ratios. In the case of NYSE:NVO, the assigned 7 reflects its health status:
ChartMill utilizes a Profitability Rating to assess stocks, scoring them on a scale of 0 to 10. This rating takes into account a variety of profitability ratios and margins, both in absolute terms and in comparison to industry peers. NYSE:NVO has earned a 9 out of 10:
More Best Dividend stocks can be found in our Best Dividend screener.
Check the latest full fundamental report of NVO for a complete fundamental analysis.
This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.
NOVO-NORDISK A/S-SPONS ADR
NYSE:NVO (4/26/2024, 7:07:16 PM)
Premarket: 126.92 +0.07 (+0.06%)126.85
+1.06 (+0.84%)
The "Magnificent Seven" stocks dominate the artificial intelligence (AI) arena. One notable hedge fund manager has three in his top 10 holdings.
The biotech's weight loss drug candidate could fuel a premium-laden buyout, but risks abound.
These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.
Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.
Why NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) qualifies as a quality stock.
These three biotech stocks, with robust fundamentals and long-term prospects represent the sector’s finest at this time.
Lilly recently announced news that could solve a big problem.
These weight loss drug stocks are relatively unknown and brimming with potential following the massive success of Novo Nordisk and Eli Lilly.
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
These two pharma stocks have followed distinct paths of late. Which is the better investment?
These stocks to buy are set to surpass analyst expectations, with exciting product and service developments sparking unforeseen growth.